Panel Discussion: The Future of HPAPIs, Cost/Risk Analysis & Advanced Manufacturing

Time: 10:00 am
day: Day One


As pipelines become more potent, for which indications is costly single nanogram containment cost beneficial for? Contrasting rare disease and wide-spread indications
How can we better target drugs to efficaciously apply HPAPI’s for patient benefit?
• How are analytical cleaning methods affected, given very low (single particle like) concentrations won’t be distributed like a gas
• How can we leverage pharma 4.0 to digitalize HPAPI manufacturing, though augmented reality, digital twins and modular mobile manufacturing